Article
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Nature communications - 29 Jan 2016
Johnson Douglas B, Estrada Monica V, Salgado Roberto, Sanchez Violeta, Doxie Deon B, Opalenik Susan R, Vilgelm Anna E, Feld Emily, Johnson Adam S, Greenplate Allison R, Sanders Melinda E, Lovly Christine M, Frederick Dennie T, Kelley Mark C, Richmond Ann, Irish Jonathan M, Shyr Yu, Sullivan Ryan J, Puzanov Igor, Sosman Jeffrey A, Balko Justin M
Abstract excerpt
Anti-PD-1 therapy yields objective clinical responses in 30-40% of advanced melanoma patients. Since most patients do not respond, predictive biomarkers to guide treatment selection are needed. We hypothesize that MHC-I/II expression is required for tumour antigen presentation and may predict anti-PD-1 therapy response. In this study, across 60 melanoma cell lines, we find bimodal expression patterns of MHC-II,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.